H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)

MannKind Corporation (NASDAQ:MNKD) is one of the best long-term penny stocks to buy right now. On August 25, H.C. Wainwright reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), setting a $9 price target.

The firm told investors in a research note that it considers the company’s scPharmaceuticals acquisition positively, adding that it expects MannKind Corporation’s (NASDAQ:MNKD) shares to benefit from a more diversified revenue base.

It added that MannKind Corporation (NASDAQ:MNKD) paid a “very reasonable” price for the acquisition.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases.

The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.